The study reported in the Journal of Clinical Investigation, shows that HBV goes through two stages to create a drug-resistant virus with the ability to achieve fast replication.
Researcher Suzane Kioko Ono, of the University of Tokyo, Japan, and colleagues from Sao Paulo, Brazil, and Atlanta, Georgia, USA, tested 11 antiviral compounds on HBV-infected hepatoma cells.
The compounds were tested on five mutant viruses and on the wild-type virus.
The research showed that polymerase point mutants could create drug resistance - but their ability to replicate was slowed considerably.
|The purine analogue entecavir has a 1000-fold greater potency than lamivudine.
|Journal of Clinical Investigation|
A further mutation then restored the ability of the virus to replicate.
"One drug, the purine analogue entecavir, stands out because of its thousand-fold greater potency than lamivudine and its ability to suppress replication of even the most vigorous drug-resistant mutants," the researchers reported.
Report Copyright: Englemed Health News at http://www.internationalmedicalnews.com